Fighting cancer through research. You can support us by making a donation, however large or small.
IELSG37 – A randomized trial of observation versus radiotherapy in primary mediastinal B-cell lymphoma patients with complete metabolic response after standard immunochemotherapy
IELSG39 – The IELSG39 trial: efficacy of first-line chlamydia psitaci eradication with a six-month regimen of doxycycline in patients with stage-I MALT lymphoma of ocular adnexae
IELSG43 – Consolidative HCT-ASCT is superior to non-myeloablative chemo-immuotherapy in newly-diagnosed PCNSL – Updated results of the randomized phase IIMATRix/IELSG43 trial
IELSG47 – Rituximab and ibrutinib combination is safe and effective in untreated splenic and nodal marginal zone lymphomas: planned subset analysis of the IESLG47/MALIBU phase II study
IELSG35 – Primary lymphoma of the female genital tract: a retrospective survey of the International Extranodal Lymphoma Study Group
The next Annual Meeting of the International Extranodal Lymphoma Study Group (IELSG) will be held on March 8-9, 2024 in Stresa (Italy) at Hotel La Palma.
More information will follow soon.